EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Standardized Management Pathway to Prevent Acute Rejection After Liver Transplantation Following ICI Therapy for Downstaging HCC

Ning Wang, Zebin Zhu, Hao Zheng, Can Qi, Xiaodong Yuan, Xuefeng Li, Zhijun Xu, Jiwei Qin, Wei Wu, Jizhou Wang, Ruipeng Song, Zhiyong Guo and 3 more

Health Care Science · 2026-06 · 5 (3) · 196-206

DOI: 10.1002/hcs2.70071 ↗

At a glance

Journal article in Health Care Science, published online on 2026-04-23. Written by Ning Wang and 14 co-authors. Institution: The Transplantation Center, First Affiliated Hospital, School of Life Sciences and Medical Center University of Sciences & Technology of China Hefei …. Cited 1 times so far (Crossref); 32 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Anhui Department of Education.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Immune checkpoint inhibitors (ICIs) have shown promise in downstaging hepatocellular carcinoma (HCC) for liver transplantation (LT), enabling previously ineligible patients to meet transplant criteria. However, their use raises concerns about post‐transplant acute rejection (AR) based on data lacking information regarding standardized management pathways and notably perioperative protocols, including immunosuppression protocols and monitoring.

Methods

This study evaluated 59 LT recipients divided into three groups (two control groups), including 13 ICI‐exposed patients (third group). All groups followed a standardized immunosuppression protocol and monitoring embedded into an enhanced recovery after surgery (ERAS) protocol, featuring basiliximab and steroid induction, early mammalian target of rapamycin inhibitor (mTOR) use, and reduced tacrolimus dosing.

Results

Despite varied ICI washout intervals (median 36 days), no AR episodes were observed in any group. One‐year overall survival and recurrence‐free survival were 93%/85% and 100%/85% in standard patients, and 77%/69% in ICI‐exposed patients, respectively. The most frequent complications were biliary and infectious, with no significant intergroup differences.

Conclusions

These findings suggest that in a standardized clinical pathway with structured immunosuppressive protocols, therapeutic drug monitoring, and early complication surveillance, LT can be safely performed after ICI exposure without increasing rejection risk. The study underscores the need for standardized clinical pathways and consistent reporting of immunosuppressive regimens to optimize outcomes in this emerging patient population.

Subjects

Author keywords

acute rejectionenhanced recovery after liver transplantationhepatocellular carcinomaimmune checkpoint inhibitor therapyimmunosuppression protocolperioperative protocolquality managementstandardized management pathway

Authors and institutions

  • The Transplantation Center, First Affiliated Hospital, School of Life Sciences and Medical Center University of Sciences & Technology of China Hefei China.
  • Organ Transplant Centre, The First Affiliated Hospital Sun Yat-sen University Guangzhou China.
  • Guangdong Provincial Key Laboratory of Organ Donation and Transplant Immunology Guangzhou China.
  • Guangdong Provincial International Cooperation Base of Science and Technology (Organ Transplantation) Guangzhou China.
  • NHC Key Laboratory of Assisted Circulation (Sun Yat-sen University) Guangzhou China.
  • Research Centre of Big Data and Artificial Intelligence of Medicine The First Affiliated Hospital of Sun Yat-sen University Guangzhou China.

ORCID profiles: Björn Nashan

Funding

  • Anhui Department of Education

Cite

APA

Wang, N., Zhu, Z., Zheng, H., Qi, C., Yuan, X., Li, X., Xu, Z., Qin, J., Wu, W., Wang, J., Song, R., Guo, Z., Liu, L., Zhang, S. G., & Nashan, B. (2026). Standardized Management Pathway to Prevent Acute Rejection After Liver Transplantation Following ICI Therapy for Downstaging HCC. Health Care Science, 5(3), 196-206. https://doi.org/10.1002/hcs2.70071

Vancouver

Wang N, Zhu Z, Zheng H, Qi C, Yuan X, Li X, et al. Standardized Management Pathway to Prevent Acute Rejection After Liver Transplantation Following ICI Therapy for Downstaging HCC. Health Care Science. 2026;5(3):196-206. doi:10.1002/hcs2.70071

BibTeX
@article{Wang2026,
  author = {Wang, Ning and Zhu, Zebin and Zheng, Hao and Qi, Can and Yuan, Xiaodong and Li, Xuefeng and Xu, Zhijun and Qin, Jiwei and Wu, Wei and Wang, Jizhou and Song, Ruipeng and Guo, Zhiyong and Liu, Lianxin and Zhang, Shu-Geng and Nashan, Björn},
  title = {Standardized Management Pathway to Prevent Acute Rejection After Liver Transplantation Following ICI Therapy for Downstaging HCC},
  journal = {Health Care Science},
  year = {2026},
  volume = {5},
  number = {3},
  pages = {196--206},
  doi = {10.1002/hcs2.70071}
}
Start for free →